Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia.

@article{Lanvers2003PharmacologyOA,
  title={Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia.},
  author={Claudia Lanvers and Dirk Reinhardt and Angelika Duebbers and Alexandra Wagner-Bohn and Ursula Creutzig and Joerg Ritter and Joachim Boos},
  journal={Medical and pediatric oncology},
  year={2003},
  volume={40 5},
  pages={
          293-301
        }
}
BACKGROUND Due to severe side effects in virtually all children treated with a standard dose of 45 mg/m(2)/day all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) the AML-BFM study group reduced the dosage to 25 mg/m(2)/day. For the lack of data on the use of ATRA at this dosage in children with APL, the study group further decided to evaluate the pharmacokinetics and metabolism of ATRA in children. PROCEDURE Twenty-three pharmacokinetic and metabolic profiles of ATRA were… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS